Veru Reports Narrowed Q2 Loss, Boosts Cash to $27.6M, and Advances Obesity Trial

summarizeSummary

Veru Inc. announced a narrowed Q2 net loss and a significant increase in cash to $27.6 million, bolstering its financial position and advancing its key obesity clinical trial.

check_boxKey Events

• Narrowed Net Loss

  The company reported a net loss of $2.7 million, or $0.12 per share, for Q2 fiscal 2026, a significant reduction from $7.9 million, or $0.54 per share, in the prior year.

• Substantial Cash Increase

  Cash, cash equivalents, and restricted cash increased to $27.6 million as of March 31, 2026, up from $15.8 million on September 30, 2025. This increase was largely due to $23.3 million in financing activities.

• Addressing Going Concern

  The significant cash infusion and improved liquidity directly address the 'going concern' warning previously disclosed, providing critical financial runway for operations and clinical development.

• Clinical Trial Progress

  The Phase 2b PLATEAU clinical trial, evaluating enobosarm in combination with semaglutide for obesity, is actively enrolling patients and remains on track for an interim analysis in Q1 calendar year 2027.

auto_awesomeAnalysis

Veru Inc. reported a significantly narrowed net loss for Q2 fiscal 2026 and a substantial increase in its cash reserves to $27.6 million, primarily driven by $23.3 million in financing activities. This improved liquidity directly addresses the company's previously disclosed 'going concern' warning and provides crucial runway for its clinical programs. The progress in the Phase 2b PLATEAU clinical trial for enobosarm, with interim analysis expected in Q1 2027, provides a positive operational update.